Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 19/20 | 0.54 |
| ▸ | LOX | P28300 | 6/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27316040 | 0.90 | LOXL2 (0.45) | LOXL2LOXIKBKBCHUKLCK | |
| SCHEMBL15390231 | 0.87 | LOXL2 (0.44) | LOXL2LOXROCK1 | |
| SCHEMBL30771875 | 0.85 | LOXL2 (0.43) | LOXL2LOX | |
| SCHEMBL6121329 | 0.85 | LOXL2 (0.43) | LOXL2LOX | |
| SCHEMBL15390719 | 0.85 | LOXL2 (0.43) | LOXL2LOX | |
| SCHEMBL8545951 | 0.84 | LOXL2 (0.42) | LOXL2LOX | |
| SCHEMBL8543452 | 0.83 | LOXL2 (0.44) | LOXL2LOX | |
| SCHEMBL8579703 | 0.83 | LOXL2 (0.44) | LOXL2LOX | |
| SCHEMBL22622482 | 0.82 | LOXL2 (0.60) | LOXL2LOX | |
| SCHEMBL8577429 | 0.82 | LOXL2 (0.41) | LOXL2LOXROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022125670-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021076124-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021072098-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3795152-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019191679-A1 | BIOMARKERS FOR INFLAMMATORY SKIN DISEASE | INCYTE CORPORATION (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019161098-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORPORATION (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2017035366-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2012068450-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |